Elbasvir

Category	Hepatitis C Virus (HCV)
CAS	1370468-36-2
Description	Elbasvir has been found to restrain viral phosphoprotein so that could be used against hepatitis C virus and is currently under Phase II trail.

Quotation Now

Product Information

Synonyms	Elbasvir; MK-8742; UNII-632L571YDK; 632L571YDK; MK8742; MK 8742
Molecular Weight	882.02
Molecular Formula	C49H55N9O7
Canonical SMILES	CC(C)C(C(=O)N1CCCC1C2=NC=C(N2)C3=CC4=C(C=C3)N5C(OC6=C(C5=C4)C=CC(=C6)C7=CN=C(N7)C8CCCN8C(=O)C(C(C)C)NC(=O)OC)C9=CC=CC=C9)NC(=O)OC
InChI	InChI=1S/C49H55N9O7/c1-27(2)41(54-48(61)63-5)45(59)56-20-10-14-37(56)43-50-25-34(52-43)30-17-19-36-32(22-30)23-39-33-18-16-31(24-40(33)65-47(58(36)39)29-12-8-7-9-13-29)35-26-51-44(53-35)38-15-11-21-57(38)46(60)42(28(3)4)55-49(62)64-6/h7-9,12-13,16-19,22-2
InChIKey	BVAZQCUMNICBAQ-PZHYSIFUSA-N
Purity	98%
Density	1.4±0.1 g/cm3
Solubility	DMSO
Appearance	Powder
Application	Elbasvir has been found to restrain viral phosphoprotein so that could be used against hepatitis C virus and is currently under Phase II trail.
Shelf Life	As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly
Storage	-20°C Freeze
Complexity	1680
Exact Mass	881.42244513
Index Of Refraction	1.701
In Vitro	Elbasvir shows potent activity against genotype 1a and 1b replicons, with EC90 of 0.006 nM for both the wild-type 1a_H77 and 1b_con1 replicons. Elbasvir inhibits genotype 3 replicons with EC90 of 0.12 nM. Elbasvir (0.06 nM, 0.6 nM, and 6 nM) demonstrates dose-dependent suppression of resistant genotype 1a replicons, illustrated by the reductions in colony counts at higher doses. Elbasvir is highly potent against HCV replicons bearing NS5A sequences from GT1a, -1b, -2a(31L), -3a, -4a, -5a, and -6, with EC50s in the low-picomolar range.
PSA	188.80000
Target	EC50: 4 nM (HCV 1a), 3 nM (HCV 1b), 3 nM (HCV 2a)
XLogP3-AA	6.7